Management of Acute Severe Hepatitis B
This patient with acute severe hepatitis B (ALT 2000, AST 1700, HBsAg+, IgM anti-HBc+, INR 1.2) should be started immediately on nucleos(t)ide analogue therapy with entecavir or tenofovir to prevent progression to acute liver failure and reduce mortality.
Diagnosis Confirmation
Your patient has acute severe hepatitis B, confirmed by:
- Markedly elevated transaminases (ALT 2000, AST 1700)
- HBsAg positive with IgM anti-HBc positive (indicating acute infection, not chronic) 1
- INR 1.2 (approaching the threshold for severe disease)
The INR of 1.2, while not yet meeting the strict definition of severe acute hepatitis B (INR >1.5), combined with the extremely elevated transaminases indicates this patient is at high risk for progression 2.
Treatment Decision: Start Antivirals NOW
Why Treat This Patient
While >95% of adults with acute hepatitis B clear the virus spontaneously, severe acute hepatitis B requires antiviral therapy 2. The evidence strongly supports early intervention:
- Mortality benefit: In a randomized controlled trial of 80 patients with severe acute hepatitis B, lamivudine reduced mortality from 25% to 7.5% 2
- Clinical improvement: Patients receiving antivirals showed significant improvement in coagulopathy and jaundice 2
- Timing is critical: Most patients who died or required transplantation despite antiviral therapy were started late in their disease course 3
The key principle: prompt and timely antiviral therapy is crucial 3. Your patient's INR of 1.2 is already trending toward the danger zone (>1.5), making this the optimal window for intervention.
Which Antiviral to Use
First-line options 2:
- Entecavir (preferred): More potent than lamivudine, higher barrier to resistance
- Tenofovir (TDF or TAF): Equally potent, high barrier to resistance
Why not lamivudine? While most historical data used lamivudine 2, 4, newer evidence suggests entecavir achieves higher HBsAg seroconversion rates (52.38% vs 23.18% at 24 weeks) 2. Given the availability of more potent agents with higher resistance barriers, entecavir or tenofovir should be preferred 3.
Dosing
- Entecavir: 0.5 mg orally once daily
- Tenofovir DF: 245 mg orally once daily
- Tenofovir AF: 25 mg orally once daily
Monitoring Strategy
Immediate monitoring (first 2 weeks):
- INR and PT daily - critical threshold is INR >1.5 2, 5, 2
- Total bilirubin every 2-3 days
- ALT/AST twice weekly
- Clinical assessment for encephalopathy, ascites
If deterioration occurs (INR >1.5, worsening jaundice, encephalopathy):
- Contact transplant center immediately 5, 6
- Continue antivirals but recognize salvage becomes challenging once coagulopathy develops 7
Ongoing monitoring (weeks 2-12):
- HBV DNA at 4 weeks to confirm viral suppression
- ALT/AST weekly until normalizing
- INR weekly
- HBsAg and anti-HBs at 3,6, and 12 months 2
Duration of Therapy
For acute hepatitis B with good response:
- Continue antivirals until HBsAg clearance occurs (typically 3-7 months) 4
- Most patients (14/15 in one series) cleared HBsAg within 3-7 months on lamivudine 4
- Protective anti-HBs antibodies develop in 3-21 months 4
If HBsAg persists >6 months:
- Patient has progressed to chronic hepatitis B
- Continue long-term antiviral therapy per chronic HBV guidelines 1
Critical Pitfalls to Avoid
Waiting for further deterioration: Don't wait for INR >1.5 or frank liver failure - early treatment is key to preventing progression 3, 7
Using lamivudine: While effective, entecavir and tenofovir are superior and should be used when available 3
Delaying transplant evaluation: If INR rises above 1.5 or bilirubin continues climbing despite antivirals, contact transplant center immediately 5, 6
Assuming spontaneous recovery: With transaminases this elevated and INR already 1.2, this patient is in the high-risk category requiring intervention 2